The Oncologic Safety of Sentinel Lymph Node Biopsy in Patients with Node-Positive Breast Cancer with Complete Response to Neoadjuvant Chemotherapy: A Single-Center Experience
Objective. To evaluate the efficiency and safety of sentinel lymph node biopsy (SLNB) in patients with breast cancer with complete response to neoadjuvant chemotherapy (NAC). Methods. Ninety-two consecutive (T1-4 and N1-2) patients with breast cancer who had pathologic and/or clinical and radiologic...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-01-01
|
| Series: | The Breast Journal |
| Online Access: | http://dx.doi.org/10.1155/2023/4549033 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849695450981990400 |
|---|---|
| author | Ismail Can Tercan Baha Zengel Ozlem Ozdemir Demet Cavdar Funda Tasli Zehra Hilal Adibelli Murat Karatas Cenk Simsek Isabel Raika Durusoy Adam Uslu |
| author_facet | Ismail Can Tercan Baha Zengel Ozlem Ozdemir Demet Cavdar Funda Tasli Zehra Hilal Adibelli Murat Karatas Cenk Simsek Isabel Raika Durusoy Adam Uslu |
| author_sort | Ismail Can Tercan |
| collection | DOAJ |
| description | Objective. To evaluate the efficiency and safety of sentinel lymph node biopsy (SLNB) in patients with breast cancer with complete response to neoadjuvant chemotherapy (NAC). Methods. Ninety-two consecutive (T1-4 and N1-2) patients with breast cancer who had pathologic and/or clinical and radiologic axillary lymph node involvement were included. All patients received NAC. Patients with a clinical and radiologic complete response in the axilla after NAC underwent SLNB. Pathologic complete response (ypCR) was defined as the absence of residual invasive and in situ cancer, and near-complete response (ypNCR) represented in situ and/or ≤ 1 mm residual tumor in the breast and/or presence of malignant cell clusters (≤0.2 mm) and/or micrometastases (≤2.0 mm) in the axillary lymph nodes (ALN) (ypTis/T1mi, ypN0i+/pN1mi). Results. The mean age of the 92 patients was 49.6 ± 10.3 years and the mean follow-up was 34.0 ± 17.8 months. With respect to breast tumors, 23 (25.0%) patients had complete and 14 (15.2%) had a near-complete response to NAC. Complete response in ALN was obtained in 39 (42.4%) patients and near-complete in six (6.5%) patients. The overall survival of the 33 patients who achieved ypCR and ypNCR was 100% and the remaining 59 patients with partial or no response to NAC was 83.1% at a mean follow-up of 34 months (p=0.063). Conclusions. In this study, no event developed in cases with ypCR and ypNCR in the breast and axilla. The persistence of the same results in long-termfollow-ups may enable the use of ypNCR as a positive prognostic marker in addition to ypCR. |
| format | Article |
| id | doaj-art-d07710ba26614b94a2898c1fe6583f82 |
| institution | DOAJ |
| issn | 1524-4741 |
| language | English |
| publishDate | 2023-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | The Breast Journal |
| spelling | doaj-art-d07710ba26614b94a2898c1fe6583f822025-08-20T03:19:46ZengWileyThe Breast Journal1524-47412023-01-01202310.1155/2023/4549033The Oncologic Safety of Sentinel Lymph Node Biopsy in Patients with Node-Positive Breast Cancer with Complete Response to Neoadjuvant Chemotherapy: A Single-Center ExperienceIsmail Can Tercan0Baha Zengel1Ozlem Ozdemir2Demet Cavdar3Funda Tasli4Zehra Hilal Adibelli5Murat Karatas6Cenk Simsek7Isabel Raika Durusoy8Adam Uslu9Department of General SurgeryDepartment of General SurgeryDepartment of Medical OncologyDepartment of PathologyDepartment of PathologyDepartment of RadiologyDepartment of General SurgeryDepartment of General SurgeryDepartment of Public HealthDepartment of General SurgeryObjective. To evaluate the efficiency and safety of sentinel lymph node biopsy (SLNB) in patients with breast cancer with complete response to neoadjuvant chemotherapy (NAC). Methods. Ninety-two consecutive (T1-4 and N1-2) patients with breast cancer who had pathologic and/or clinical and radiologic axillary lymph node involvement were included. All patients received NAC. Patients with a clinical and radiologic complete response in the axilla after NAC underwent SLNB. Pathologic complete response (ypCR) was defined as the absence of residual invasive and in situ cancer, and near-complete response (ypNCR) represented in situ and/or ≤ 1 mm residual tumor in the breast and/or presence of malignant cell clusters (≤0.2 mm) and/or micrometastases (≤2.0 mm) in the axillary lymph nodes (ALN) (ypTis/T1mi, ypN0i+/pN1mi). Results. The mean age of the 92 patients was 49.6 ± 10.3 years and the mean follow-up was 34.0 ± 17.8 months. With respect to breast tumors, 23 (25.0%) patients had complete and 14 (15.2%) had a near-complete response to NAC. Complete response in ALN was obtained in 39 (42.4%) patients and near-complete in six (6.5%) patients. The overall survival of the 33 patients who achieved ypCR and ypNCR was 100% and the remaining 59 patients with partial or no response to NAC was 83.1% at a mean follow-up of 34 months (p=0.063). Conclusions. In this study, no event developed in cases with ypCR and ypNCR in the breast and axilla. The persistence of the same results in long-termfollow-ups may enable the use of ypNCR as a positive prognostic marker in addition to ypCR.http://dx.doi.org/10.1155/2023/4549033 |
| spellingShingle | Ismail Can Tercan Baha Zengel Ozlem Ozdemir Demet Cavdar Funda Tasli Zehra Hilal Adibelli Murat Karatas Cenk Simsek Isabel Raika Durusoy Adam Uslu The Oncologic Safety of Sentinel Lymph Node Biopsy in Patients with Node-Positive Breast Cancer with Complete Response to Neoadjuvant Chemotherapy: A Single-Center Experience The Breast Journal |
| title | The Oncologic Safety of Sentinel Lymph Node Biopsy in Patients with Node-Positive Breast Cancer with Complete Response to Neoadjuvant Chemotherapy: A Single-Center Experience |
| title_full | The Oncologic Safety of Sentinel Lymph Node Biopsy in Patients with Node-Positive Breast Cancer with Complete Response to Neoadjuvant Chemotherapy: A Single-Center Experience |
| title_fullStr | The Oncologic Safety of Sentinel Lymph Node Biopsy in Patients with Node-Positive Breast Cancer with Complete Response to Neoadjuvant Chemotherapy: A Single-Center Experience |
| title_full_unstemmed | The Oncologic Safety of Sentinel Lymph Node Biopsy in Patients with Node-Positive Breast Cancer with Complete Response to Neoadjuvant Chemotherapy: A Single-Center Experience |
| title_short | The Oncologic Safety of Sentinel Lymph Node Biopsy in Patients with Node-Positive Breast Cancer with Complete Response to Neoadjuvant Chemotherapy: A Single-Center Experience |
| title_sort | oncologic safety of sentinel lymph node biopsy in patients with node positive breast cancer with complete response to neoadjuvant chemotherapy a single center experience |
| url | http://dx.doi.org/10.1155/2023/4549033 |
| work_keys_str_mv | AT ismailcantercan theoncologicsafetyofsentinellymphnodebiopsyinpatientswithnodepositivebreastcancerwithcompleteresponsetoneoadjuvantchemotherapyasinglecenterexperience AT bahazengel theoncologicsafetyofsentinellymphnodebiopsyinpatientswithnodepositivebreastcancerwithcompleteresponsetoneoadjuvantchemotherapyasinglecenterexperience AT ozlemozdemir theoncologicsafetyofsentinellymphnodebiopsyinpatientswithnodepositivebreastcancerwithcompleteresponsetoneoadjuvantchemotherapyasinglecenterexperience AT demetcavdar theoncologicsafetyofsentinellymphnodebiopsyinpatientswithnodepositivebreastcancerwithcompleteresponsetoneoadjuvantchemotherapyasinglecenterexperience AT fundatasli theoncologicsafetyofsentinellymphnodebiopsyinpatientswithnodepositivebreastcancerwithcompleteresponsetoneoadjuvantchemotherapyasinglecenterexperience AT zehrahilaladibelli theoncologicsafetyofsentinellymphnodebiopsyinpatientswithnodepositivebreastcancerwithcompleteresponsetoneoadjuvantchemotherapyasinglecenterexperience AT muratkaratas theoncologicsafetyofsentinellymphnodebiopsyinpatientswithnodepositivebreastcancerwithcompleteresponsetoneoadjuvantchemotherapyasinglecenterexperience AT cenksimsek theoncologicsafetyofsentinellymphnodebiopsyinpatientswithnodepositivebreastcancerwithcompleteresponsetoneoadjuvantchemotherapyasinglecenterexperience AT isabelraikadurusoy theoncologicsafetyofsentinellymphnodebiopsyinpatientswithnodepositivebreastcancerwithcompleteresponsetoneoadjuvantchemotherapyasinglecenterexperience AT adamuslu theoncologicsafetyofsentinellymphnodebiopsyinpatientswithnodepositivebreastcancerwithcompleteresponsetoneoadjuvantchemotherapyasinglecenterexperience AT ismailcantercan oncologicsafetyofsentinellymphnodebiopsyinpatientswithnodepositivebreastcancerwithcompleteresponsetoneoadjuvantchemotherapyasinglecenterexperience AT bahazengel oncologicsafetyofsentinellymphnodebiopsyinpatientswithnodepositivebreastcancerwithcompleteresponsetoneoadjuvantchemotherapyasinglecenterexperience AT ozlemozdemir oncologicsafetyofsentinellymphnodebiopsyinpatientswithnodepositivebreastcancerwithcompleteresponsetoneoadjuvantchemotherapyasinglecenterexperience AT demetcavdar oncologicsafetyofsentinellymphnodebiopsyinpatientswithnodepositivebreastcancerwithcompleteresponsetoneoadjuvantchemotherapyasinglecenterexperience AT fundatasli oncologicsafetyofsentinellymphnodebiopsyinpatientswithnodepositivebreastcancerwithcompleteresponsetoneoadjuvantchemotherapyasinglecenterexperience AT zehrahilaladibelli oncologicsafetyofsentinellymphnodebiopsyinpatientswithnodepositivebreastcancerwithcompleteresponsetoneoadjuvantchemotherapyasinglecenterexperience AT muratkaratas oncologicsafetyofsentinellymphnodebiopsyinpatientswithnodepositivebreastcancerwithcompleteresponsetoneoadjuvantchemotherapyasinglecenterexperience AT cenksimsek oncologicsafetyofsentinellymphnodebiopsyinpatientswithnodepositivebreastcancerwithcompleteresponsetoneoadjuvantchemotherapyasinglecenterexperience AT isabelraikadurusoy oncologicsafetyofsentinellymphnodebiopsyinpatientswithnodepositivebreastcancerwithcompleteresponsetoneoadjuvantchemotherapyasinglecenterexperience AT adamuslu oncologicsafetyofsentinellymphnodebiopsyinpatientswithnodepositivebreastcancerwithcompleteresponsetoneoadjuvantchemotherapyasinglecenterexperience |